Journal
PEDIATRIC BLOOD & CANCER
Volume 46, Issue 5, Pages 579-585Publisher
WILEY
DOI: 10.1002/pbc.20644
Keywords
JMML; leukemia; Noonan syndrome; neurofibromatosis; RAS
Categories
Funding
- NCI NIH HHS [CA104282, CA72614, U01CA84221, T32CA09043, K08CA103868] Funding Source: Medline
Ask authors/readers for more resources
Identifying the molecular basis for inherited cancer predispositions reveals genes that when Mutated, play a critical role in the earliest stages of tumorigenesis. Although rare, inherited predispositions to myeloid leukemias have led to a greater understanding of pathways important for myeloid proliferation and maturation. In particular, elucidating why children with neurofibromatosis type 1 (NF1) and Noonan syndrome (NS) are predisposed to juvenile myelomonocytic leukemia (JMML) has uncovered a critical role of hyperactive Ras signaling in normal myeloid growth and leukemo-genesis. Here, we review studies of human samples and experiments performed in genetically engineered strains of mice investigating the molecular and biochemical basis of aberrant growth in JMML. These strains model human disease features and provide an opportunity to investigate novel therapeutic strategies that may ultimately cure JMML and other myeloid malignancies characterized by hyperactive Ras.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available